ProPhase Labs
PRPH • NASDAQ
ProPhase Labs is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Ted William Karkus, with a market cap of $4.9M.
CEOTed William Karkus
Market Cap$4.9M
Drug Manufacturers - Specialty & Generic
Healthcare
Employees113.0
Websiteprophaselabs.com
Next Earnings
Upcoming earnings announcement for ProPhase Labs
Date
Tuesday, May 19, 2026 (in 2 months)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.12
Earnings History
Past 12 earnings reports for ProPhase Labs
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 19, 2025 | Q3 2025 | -$0.16Est: -$0.11 | -45.5% | $883.0KEst: $5.7M | -84.5% |  10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.11Est: -$0.15 | +26.7% | $1.2MEst: $3.6M | -64.9% | 10-Q |
| May 20, 2025 | Q1 2025 | -$0.13Est: -$0.18 | +27.8% | $1.4MEst: $2.5M | -41.6% | 10-Q |
| Mar 31, 2025 | Q4 2024 | -$1.59Est: -$1.27 | -25.2% | -$2.5MEst: $13.0M | -118.8% | 10-K/A |
| Nov 13, 2024 | Q3 2024 | -$0.35Est: $0.04 | -975.0% | $3.1MEst: $23.9M | -86.8% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.33Est: -$0.24 | -37.5% | $2.5MEst: $11.2M | -77.9% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.07Est: -$0.28 | +75.0% | $3.6MEst: $9.9M | -63.1% | 10-Q |
| Mar 15, 2024 | Q4 2023 | -$0.51Est: -$0.26 | -96.2% | $4.4MEst: $10.7M | -59.3% | 10-K/A |
| Nov 9, 2023 | Q3 2023 | -$0.30Est: -$0.19 | -57.9% | $8.4MEst: $13.1M | -35.9% | — |
| Aug 10, 2023 | Q2 2023 | -$0.20Est: -$0.14 | -42.9% | $13.2MEst: $14.1M | -6.5% | 10-Q |
| May 11, 2023 | Q1 2023 | $0.03Est: -$0.09 | +133.3% | $19.3MEst: $16.3M | +18.4% | — |
| Mar 28, 2023 | Q4 2022 | -$0.08Est: $0.02 | -500.0% | $21.8MEst: $20.5M | +6.4% | — |